Methods for treating psychosis associated with interferson-α therapy
View Patent ↗The present invention relates to the treatment of psychosis associated with interferon-α therapy by administering an amount of a glucocorticoid receptor antagonist effective to ameliorate the symptoms of psychosis in the patient, wherein the patient is not otherwise in need of treatment with a glucocorticoid receptor antagonist. The present invention further relates to kits for the treatment of Hepatitis C infection in a patient.
1. A method of ameliorating the symptoms of psychosis associated with interferon α therapy in a patient, comprising:
administering to the patient having received interferon α therapy and suffering from psychosis associated with the interferon α therapy, an amount of a glucocorticoid receptor antagonist effective to ameliorate the symptoms of psychosis in the patient, with the proviso that the patient is not otherwise in need of treatment with a glucocorticoid receptor antagonist.
2. The method of claim 1 , wherein the glucocorticoid receptor antagonist comprises a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton.
3. The method of claim 2 , wherein the phenyl-containing moiety in the 11-beta position of the steroidal skeleton is a dimethylaminophenyl moiety.
4. The method of claim 3 , wherein the glucocorticoid receptor antagonist comprises mifepristone.
5. The method of claim 3 wherein the glucocorticoid receptor antagonist is selected from the group consisting of 11-β-(4-dimethyl-aminoethoxyphenyl)-17α-propynyl-17β-hydroxy-4,9-estradien-3-one, and 17β-hydrox-17α-19-(4-methyl-phenyl)androsta -4,9 (11)-dien-3-one.
6. The method of claim 1 wherein the glucocorticoid receptor antagonist is selected from the group consisting 4α(S)-Benzyl-2(R)-prop-1-ynyl -1,2,3,4,4α,9,10,10 a (R)-octahydro-phenanthrene-2,7-diol and 4α(S)-Benzyl-2(R)-chloroethynyl -1,2,3,4,4α,9,10,10 a (R)-octahydro-phenanthrene-2,7-diol.
7. The method of claim 1 , wherein the glucocorticoid receptor antagonist is (11β,17β)-11-(1,3-benzodioxo-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one.
8. The method of claim 1 , wherein the glucocorticoid receptor antagonist is administered to the patient concomitantly with interferon-α.
9. The method of claim 8 , wherein the glucocorticoid receptor antagonist is administered to the patient throughout the course of interferon-α therapy.
10. The method of claim 8 , wherein the glucocorticoid receptor antagonist is administered to the patient concomitantly with interferon-α and a second therapeutic agent.
11. The method of claim 10 , wherein the second therapeutic agent is an anti-viral agent.
12. The method of claim 11 , wherein the anti-viral agent is ribavirin.
13. The method of claim 1 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 0.5 to about 25 mg per kilogram of body weight per day.
14. The method of claim 13 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 1 to about 4 mg per kilogram of body weight per day.
15. The method of claim 1 , wherein the mode of administration is selected from the group consisting of oral administration, transdermal application, nebulized suspension, and aerosol spray.
16. The method of claim 1 , wherein the patient is suffering from a viral infection caused by a virus selected from the group consisting of hepatitis C virus, hepatitis B virus, and hepatitis D virus.
17. The method of claim 16 , wherein the viral infection is acute or chronic.
18. The method of claim. 1 , wherein the patient is suffering from chronic myelogenous leukemia, HIV, Human T-Cell Lymphotropic Virus or cancer.
19. The method of claim 1 , wherein the patient has a history of substance abuse.